Free Trial

BeOne Medicines (ONC) Stock Price, News & Analysis

BeOne Medicines logo
$337.57 +3.17 (+0.95%)
As of 03:52 PM Eastern

About BeOne Medicines Stock (NASDAQ:ONC)

Advanced

Key Stats

Today's Range
$334.40
$339.67
50-Day Range
$252.14
$351.13
52-Week Range
$170.99
$351.27
Volume
86,759 shs
Average Volume
422,374 shs
Market Capitalization
$37.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$336.30
Consensus Rating
Buy

Company Overview

BeOne Medicines Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
37th Percentile Overall Score

ONC MarketRank™: 

BeOne Medicines scored higher than 37% of companies evaluated by MarketBeat, and ranked 717th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Upside/Downside

    The consensus price target for BeOne Medicines is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    BeOne Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about BeOne Medicines' stock forecast and price target.
  • Earnings Growth

    Earnings for BeOne Medicines are expected to grow in the coming year, from ($5.82) to $0.71 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BeOne Medicines is -195.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BeOne Medicines is -195.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BeOne Medicines has a P/B Ratio of 9.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.37% of the float of BeOne Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    BeOne Medicines has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    BeOne Medicines does not currently pay a dividend.

  • Dividend Growth

    BeOne Medicines does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.37% of the float of BeOne Medicines has been sold short.
  • Short Interest Ratio / Days to Cover

    BeOne Medicines has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    BeOne Medicines has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for BeOne Medicines this week, compared to 7 articles on an average week.
  • Search Interest

    13 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 333% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,824,367.00 in company stock.

  • Percentage Held by Insiders

    Only 6.62% of the stock of BeOne Medicines is held by insiders.

  • Percentage Held by Institutions

    48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BeOne Medicines' insider trading history.
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BeOne Medicines and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONC Stock News Headlines

John Oyler Sells 27,803 Shares of BeOne Medicines (NASDAQ:ONC) Stock
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
BeOne Medicines (NASDAQ:ONC) Insider Sells 122 Shares
Barclays Begins Coverage on BeOne Medicines (NASDAQ:ONC)
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

BeOne Medicines' stock was trading at $223.50 at the start of the year. Since then, ONC stock has increased by 51.6% and is now trading at $338.86.

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) posted its quarterly earnings data on Wednesday, August, 6th. The company reported $0.84 EPS for the quarter, topping the consensus estimate of $0.48 by $0.36. The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.24 billion. BeOne Medicines had a negative trailing twelve-month return on equity of 1.22% and a negative net margin of 3.89%.

Top institutional shareholders of BeOne Medicines include Primecap Management Co. CA (4.64%), Temasek Holdings Private Ltd (0.92%), Marshall Wace LLP (0.43%) and Baird Financial Group Inc. (0.31%). Insiders that own company stock include Bros Advisors Lp Baker, Aaron Rosenberg, Xiaodong Wang, Xiaobin Wu, Titus B Ball, Lai Wang, Lai Wang, John Oyler, Corazon (Corsee) D Sanders, Corazon (Corsee) D Sanders and Chan Henry Lee.
View institutional ownership trends
.

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/06/2025
Today
9/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONC
Previous Symbol
NASDAQ:ONC
CIK
1651308
Web
N/A
Fax
N/A
Employees
11,000
Year Founded
N/A

Price Target and Rating

High Price Target
$385.00
Low Price Target
$259.00
Potential Upside/Downside
-0.5%
Consensus Rating
Buy
Rating Score (0-4)
3.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$644.79 million
Net Margins
-3.89%
Pretax Margin
-1.39%
Return on Equity
-1.22%
Return on Assets
-0.72%

Debt

Debt-to-Equity Ratio
0.04
Current Ratio
1.95
Quick Ratio
1.72

Sales & Book Value

Annual Sales
$3.81 billion
Price / Sales
9.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$34.10 per share
Price / Book
9.92

Miscellaneous

Outstanding Shares
109,660,000
Free Float
102,403,000
Market Cap
$37.08 billion
Optionable
N/A
Beta
0.21
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ONC) was last updated on 9/22/2025 by MarketBeat.com Staff
From Our Partners